Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane
- 431 Downloads
- 5 Citations
Abstract
Purpose
Dexrazoxane is an established treatment option in extravasation of the classic anthracyclines such as doxorubicin, epirubicin, and daunorubicin. However, it is not known whether the protection against the devastating tissue injuries extends into extravasation with new types of anthracyclines, the anthracenediones, or the liposomal pegylated anthracycline formulations. We therefore tested the antidotal efficacy of dexrazoxane against extravasation of amrubicin, mitoxantrone, and liposomal pegylated doxorubicin in mice.
Methods
A total of 80 female B6D2F1 mice were tested in an established mouse extravasation model. The mice had experimental extravasations of amrubicin, mitoxtanrone, and Caelyx and were immediately hereafter treated with systemic dexrazoxane or saline.
Results and conclusion
Systemic treatment with dexrazoxane resulted in significant protection against extravasation injuries from all three drugs. Moreover, the vesicant potential of the three test drugs was weaker than seen in previous experiments with the classic anthracyclines.
Keywords
Extravasation Dexrazoxane Amrubicin Liposomal pegylated doxorubicin MitoxantroneReferences
- 1.Langer SW, Sehested M, Jensen PB (2000) Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 6:3680–3686PubMedGoogle Scholar
- 2.Langer SW, Sehested M, Jensen PB (2001) Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol 12:405–410PubMedCrossRefGoogle Scholar
- 3.Langer SW, Thougaard AV, Sehested M, Jensen PB (2006) Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol 57:125–128PubMedCrossRefGoogle Scholar
- 4.Thougaard AV, Langer SW, Hainau B, Grauslund M, Juhl BR, Jensen PB, Sehested M (2010) A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage. Toxicology 269(1):67–72PubMedCrossRefGoogle Scholar
- 5.Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrom K, Jensen PB, Giaccone G (2007) Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 18(3):546–550PubMedCrossRefGoogle Scholar
- 6.Wengström Y, Margulies A (2008) European oncology nursing task force: European oncology nursing society extravasation guidelines. Eur J Oncol Nurs 12:357–361PubMedCrossRefGoogle Scholar
- 7.Poplovich M, Whitford JM, Olsen M (2009) Chemotherapy and biotherapy guidelines and recommendations for practice, 3rd edn. Oncology Nursing Society, PittsburgGoogle Scholar
- 8.Luke E (2005) Mitoxantrone-induced extravasation. Oncol Nurs Forum 32(1):27–29PubMedCrossRefGoogle Scholar
- 9.Lokich J (1999) Doxil extravasation injury: a case report. Ann Oncol 10(6):735–736PubMedCrossRefGoogle Scholar